{
    "clinical_study": {
        "@rank": "35155", 
        "arm_group": [
            {
                "arm_group_label": "SB-480848 40 mg", 
                "arm_group_type": "Experimental", 
                "description": "SB-480848 40 milligrams (mg) once a day (od) for 14 +/- 4 days followed by carotid endarterectomy. SB-480848 40 mg was administered as 2 SB-480848 20 mg tablets plus 2 placebo tablets."
            }, 
            {
                "arm_group_label": "SB-480848 80 mg", 
                "arm_group_type": "Experimental", 
                "description": "SB-480848 80 mg od for 14 +/- 4 days followed by carotid endarterectomy.SB-480848 80 mg was administered as 4 20 mg SB-480848 tablets."
            }, 
            {
                "arm_group_label": "Matching Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo for 14 +/- 4 days followed by carotid endarterectomy. Placebo was administered as 4 placebo tablets. Placebo tablets were identical in appearance to the SB-480848 20 mg tablets."
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective is to determine Lp-PLA2 activity in atherosclerotic carotid plaques\n      after 14 (+/-4) days treatment with darapladib, compared to placebo.  Secondary objectives\n      include determination of the change in Lp-PLA2 activity in blood, Lp-PLA2 mass in blood and\n      plaque, specified biomarkers in blood and plaque and their respective correlation's with\n      Lp-PLA2.  In addition, the study aims to characterise the PK/PD of repeat oral doses of\n      SB-480848, and safety and tolerability in this population."
        }, 
        "brief_title": "Study to Determine the Effect of 14 Days Dosing With Darapladib (SB-480848) on Carotid Plague Composition in Patients With Planned Carotid Endarterectomy", 
        "completion_date": {
            "#text": "July 2003", 
            "@type": "Actual"
        }, 
        "condition": "Atherosclerosis", 
        "condition_browse": {
            "mesh_term": [
                "Atherosclerosis", 
                "Carotid Artery Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female, >35 years of age\n\n          -  Females of childbearing potential must be using approved contraceptive measures\n\n          -  Male patients must be willing to abstain from sexual intercourse or use a form of\n             contraception if engaging in sexual intercourse with a woman who could become\n             pregnant\n\n          -  Planned carotid endarterectomy within a timeframe compatible with recruitment for the\n             study and able to comply with the requirements of the study, as deemed by the\n             investigator\n\n          -  Written, informed consent to participate\n\n        Exclusion Criteria:\n\n          -  Recent myocardial infarction (within the previous 4 weeks)\n\n          -  Currently taking corticosteroids, warfarin, digoxin or a potent CYP3A4 inhibitor\n\n          -  Recent (<3 months) or ongoing acute infection or significant trauma associated with\n             bruising and/or taking antibiotics.  Prophylactic antibiotics for surgery are allowed\n\n          -  Change in dose of lipid-lowering therapy during the previous 4 weeks from\n             randomisation\n\n          -  History of chronic liver disease (e.g. cirrhosis, hepatitis) OR ALT OR AST \u22651.5 times\n             the upper limit of normal (ULN) at screening\n\n          -  Diagnosis of systemic lupus erythematosis (SLE) or rheumatoid arthritis (RA)\n\n          -  Clinically significant anaemia\n\n          -  History of severe renal impairment (serum creatinine >1.8mg/dL)\n\n          -  Unstable angina\n\n          -  History of asthma , anaphylaxis or anaphylactoid reactions, severe allergic responses\n\n          -  Abuse of alcohol or drugs within the last 6 months\n\n          -  Any factor or clinical disease state that, in the investigator's opinion, would\n             preclude completion of a safe surgical procedure and/or completion of the study\n\n          -  Use of an investigational drugs within 30 days or 5 half-lives of their last dose\n             prior to starting the study, whichever is the longest"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "35 Years"
        }, 
        "enrollment": {
            "#text": "103", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 31, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01916720", 
            "org_study_id": "480848/010"
        }, 
        "intervention": [
            {
                "arm_group_label": "SB-480848 40 mg", 
                "description": "Study Drug", 
                "intervention_name": "SB-480848 40 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "SB-480848 80 mg", 
                "description": "Study Drug", 
                "intervention_name": "SB-480848 80 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "SB-480848 40 mg", 
                    "Matching Placebo"
                ], 
                "description": "Study Drug", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "August 22, 2013", 
        "number_of_arms": "3", 
        "official_title": "A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Effect of the Lp-PLA2 Inhibitor SB-480848 (40, 80mg od) on Carotid Plaque Composition in Patients With Carotid Artery Disease and Planned Carotid Endarterectomy, Stratified for Statin Use and Gender, After 14+/-4 Days Treatment", 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2003", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Lp-PLA2 activity in the atherosclerotic plaque removed during carotid endarterectomy", 
            "safety_issue": "No", 
            "time_frame": "14 +/- 4 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01916720"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Lp-PLA2 mass in plaque removed during the carotid endarterectomy", 
                "safety_issue": "No", 
                "time_frame": "14 +/- 4 days"
            }, 
            {
                "measure": "Lp-PLA2 mass and activity in blood", 
                "safety_issue": "No", 
                "time_frame": "14 +/- days"
            }, 
            {
                "description": "Lipids: total cholesterol, HDL, LDL, and triglycerides Non-Lipids: hsCRP, CD40L, ICAM-1, E-selectin, PAI-1 antibody, PAI-1 antigen, and MMP-9", 
                "measure": "Lipid and Non-Lipid Biomarkers in Plasma", 
                "safety_issue": "No", 
                "time_frame": "14 +/- days"
            }, 
            {
                "description": "Oxidised Lipids and Their Metabolites: total lyso-PC, total phospholipid, and total phosphatidylcholine Biomarkers: CD68 (macrophages), CD3 (T cells), CD20 or CD22 (B cells), alpha-actin (smooth muscle cells), CD40L, MMP-2, MMP-9, PAI-1, ICAM-1, IL-6, and Lp-PLA2 (mRNA expression)", 
                "measure": "Oxidised Lipids and Their Metabolites, and Biomarkers in Plaque", 
                "safety_issue": "No", 
                "time_frame": "14 +/- 4 days"
            }
        ], 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2003", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}